Crescent Biopharma (NASDAQ:CBIO) COO Jonathan Mcneill Sells 731 Shares

Crescent Biopharma, Inc. (NASDAQ:CBIO) COO Jonathan McNeill sold 731 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $17.90, for a total transaction of $13,084.90. Following the transaction, the chief operating officer directly owned 138,427 shares of the company’s stock, valued at $2,477,843.30. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jonathan Mcneill also recently made the following trade(s):

• On Friday, September 18th, Jonathan McNeill sold 3,839 shares of Crescent Biopharma stock. The shares were sold at an average price of $16.71, for a total transaction of $64,149.69.
• On Monday, June 22nd, Jonathan McNeill sold 20,549 shares of Crescent Biopharma stock. The stock was sold at an average price of $17.99, for a total transaction of $369,676.51.

Crescent Biopharma Price Performance

Shares of Crescent Biopharma stock opened at $16.89 on Friday. The firm has a fifty day moving average price of $17.12 and a 200 day moving average price of $17.43. Crescent Biopharma, Inc. has a 1 year low of $8.72 and a 1 year high of $27.41. The stock has a market cap of $627.29 million, a PE ratio of -2.51 and a beta of 1.24.

Crescent Biopharma (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($0.74) EPS for the quarter, meeting the consensus estimate of ($0.74). As a group, equities analysts expect that Crescent Biopharma, Inc. will post -2.91 EPS for the current year.

More Crescent Biopharma News

Here are the key news stories impacting Crescent Biopharma this week:

• Neutral Sentiment: CEO Joshua Brumm, COO Jonathan McNeill, CFO Richard Scalzo, and other insiders collectively sold 16,726 shares worth approximately $285,501 between September 16 and September 18. The sales reduced individual holdings by roughly 0.5% to 3.2%, but insiders continued to retain meaningful positions. SEC insider transaction filing
• Neutral Sentiment: All reported transactions were executed under pre-arranged Rule 10b5-1 trading plans and were described as sales to cover tax-withholding obligations tied to vested equity awards. That reduces the likelihood that the transactions represent a change in management’s outlook, although the aggregate selling may still weigh modestly on sentiment. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by senior executives—including the CEO and COO—could be viewed as a near-term supply or sentiment overhang. However, the relatively small percentage reductions and tax-related rationale make this a limited negative signal rather than a clear indication of weakening business prospects. SEC insider transaction filing

Wall Street Analyst Weigh In

Several research firms recently commented on CBIO. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Crescent Biopharma in a report on Friday, August 7th. TD Cowen raised Crescent Biopharma to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright restated a “neutral” rating on shares of Crescent Biopharma in a research report on Thursday, July 16th. Finally, Wedbush reaffirmed an “outperform” rating and set a $27.00 price objective on shares of Crescent Biopharma in a research note on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.60.

Institutional Investors Weigh In On Crescent Biopharma

Several hedge funds have recently modified their holdings of the company. Fcpm Iii Services B.V. acquired a new position in Crescent Biopharma in the 4th quarter worth about $19,899,000. BVF Inc. IL grew its holdings in Crescent Biopharma by 98.1% in the fourth quarter. BVF Inc. IL now owns 2,748,763 shares of the biopharmaceutical company’s stock valued at $32,600,000 after purchasing an additional 1,360,900 shares during the period. BlackRock Inc. acquired a new stake in Crescent Biopharma in the second quarter valued at approximately $22,892,000. NEXTBio Capital Management LP purchased a new stake in shares of Crescent Biopharma in the fourth quarter valued at approximately $4,422,000. Finally, Exome Asset Management LLC purchased a new stake in shares of Crescent Biopharma in the first quarter valued at approximately $2,814,000. 75.19% of the stock is owned by hedge funds and other institutional investors.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates.

Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources.

The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships.